Trials / Completed
CompletedNCT00081315
Subcutaneous Amifostine (Ethyol®) in the Prevention of Radiochemotherapy-Induced Esophagitis and Pneumonitis in Patients With Unresectable Non-Small Cell Lung Cancer
Phase II, Randomized, Double-Blind, Multicenter Trial of Subcutaneous Amifostine (Ethyol®) Versus Placebo in the Prevention of Radiochemotherapy-Induced Esophagitis and Pneumonitis in Patients With Unresectable Non-Small Cell Lung Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 130 (planned)
- Sponsor
- MedImmune LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to assess the activity of subcutaneous (SC) amifostine on the incidence and severity of acute radiochemotherapy-induced esophagitis in patients with unresectable Stage IIIA or IIIB non-small cell lung cancer (NSCLC) receiving combined modality therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Amifostine |
Timeline
- Start date
- 2003-11-01
- Completion
- 2006-08-01
- First posted
- 2004-04-09
- Last updated
- 2007-08-21
Locations
24 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00081315. Inclusion in this directory is not an endorsement.